What’s really driving RCM valuations right now, and how do you separate genuine AI innovation from smoke and mirrors? In this episode, Chanie Gluck sits down with Chad Zoretic, Managing Director and Partnerships/M&A Consulting Practice Leader at VMG Health, to unpack what’s happening beneath the surface of today’s RCM industry.

With 30+ years of experience guiding healthcare M&A deals, Chad shares an insider’s view on why purchase price multiples for RCM companies vary so widely, what buyers actually look for during due diligence, and why claiming to be “AI-enabled” isn’t enough anymore. He and Chanie dig into practical strategies for adopting new technology without overcommitting, where the biggest automation wins are (hint: front-end and back-end, not AR), and what it really takes to build a business that’s attractive to investors, whether or not you ever plan to sell.

Tune in for a candid, experience-driven conversation about technology adoption, valuation drivers, and the future of revenue cycle management.

In this episode:

• Why RCM pricing models are compressing and what’s driving purchase price multiples
• How to spot “vaporware” AI claims and what real due diligence looks like
• A pragmatic, module-by-module approach to adopting new RCM technology
• The governance and workforce shifts AI adoption demands
• What actually drives higher valuations for RCM companies preparing for a future exit

Sponsors:

https://4dglobalinc.com